placeholder image
S. B. Kim All authors
About
Publications While At HealthPartners
Highlights
selected publications
Journal Article
  • Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study. 
    Journal of Clinical Oncology. 2024
  • Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. 
    Lancet Oncology. 2017
    • Contact
    full name
  • S. B. Kim
    • Quick Info
    Publications
    Publications in the past 10 years based solely on publications while at HealthPartners. Publications in prior years appear in grey.
    Collaboration